Armis‑Capital Acquires 5.57% of Curis Inc., Boosting Institutional Interest
Armis‑Capital’s 5.57% stake in Curis, Inc. signals institutional interest in the biotech’s oncology pipeline, offering insights into the firm’s evolving ownership and market prospects.
2 minutes to read
